Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > BUSINESS
BUSINESS
- Sakigake: Now and Future (4) - MSD’s Anti-PD-1 Antibody Gets Sakigake Designation for Gastric Cancer, While Opdivo also Under Development for Same Indication
March 2, 2016
- Drug Wholesalers’ Inventory Margins Likely to Diminish for FY2016 Price Revision
March 1, 2016
- MSD Seeks Lung Cancer Indication for Pembrolizumab in Japan
March 1, 2016
- Shionogi Links Arms with Roche on Sakigake-Designated Anti-Flu Drug
March 1, 2016
- New Presidents Announced for Alfresa, Suzuken, Fuji Pharma
February 29, 2016
- Takeda Gets Approval for Blister Packs Containing Takecab for H. pylori Eradication
February 29, 2016
- Novartis Seeks Japan Approval of Malaria Drug
February 29, 2016
- GSK, Daiichi Sankyo Voluntarily Recalling Zyrtec Tablets 5
February 29, 2016
- PCSK9 Inhibitor Repatha Expected to Debut this Spring, with Competing Products to Follow
February 29, 2016
- Daiichi Sankyo Launches Japan Clinical Trial on DMD Nucleic Acid Therapy
February 26, 2016
- Sanofi Seeks to Change Lyxumia Indication to Type 2 Diabetes without Strings
February 26, 2016
- Daiichi Sankyo to Revamp Organization to Boost Cancer R&D
February 26, 2016
- Torii to Expand Sales Force to 570 by FY2018; Will Actively Seek Acquisitions, Alliances
February 26, 2016
- Astellas Seeks Japan Approval of IBS-C Treatment Linaclotide
February 25, 2016
- Mitsubishi Tanabe’s New US Unit to Explore M&A Opportunities in Its Field of Specialty
February 25, 2016
- Takeda, ASKA Announce Deal on Ecard Authorized Generic
February 25, 2016
- Rohto Aims to Enter Field of Regenerative Medicine by 2020, with Initial Focus on Fibrotic Diseases
February 25, 2016
- Kyorin Holdings to Shutter Nagano Plant in September
February 24, 2016
- Kipres AG Certain to Hit Shelves before Rivals as Reimbursement Request Filed
February 24, 2016
- Osteoporosis Drug Romosozumab Delivers Positive PIII Data: Amgen Astellas
February 24, 2016
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…